Week in Review: China Pharma Cross-Border Deals

BioAtla LLC, a San Diego-Beijing biotech, raised $45 million from the Global BIO Impact Fund to develop its antibody portfolio; Eye Tech Care, a French medical device maker, received $27 million from China's Everpine Capital for clinical studies of its ultrasound treatment for glaucoma; Pfizer acquired Treerly Health, a China OTC healthcare company; 20/20 GeneSystems of Maryland booked $4.5 million in capital for its lung cancer biomarker from Ping An Ventures; Yabao Pharma partnered with Sciecure Pharma of New Jersey to develop controlled-release generic drugs for the US and China; Medtronic formed a partnership with the city of Chengdu to manufacture advanced diabetes devices; HitGen, a Chengdu CRO, formed a drug research collaboration with Global Blood Therapeutics of the US; Lee's Pharma of Hong Kong acquired China rights to an ear infection treatment from Spain's Laboratorios Salvat; Luqa Pharma, a China dermatology products marketer, in-licensed China rights to a next-generation dermal filler; BeiGene of Beijing will start a US Phase Ia/b clinical trial of its PD-1 cancer drug; Chi-Med began a Phase I trial of a Syk inhibitor in patients with hematological malignancies; and Bayer completed construction of the first phase of a $213 million China consumer healthcare manufacturing facility in Yunan province. More details.... Stock Symbols: (NYSE: PFE) (SHA: 600351) (NYSE: MDT) (NSDQ: GBT) (HK: 0950) (XETRA: BAYN) Share this with colleagues: // //